GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Synonyms: CNTO-148 | CNTO148 | Simponi®
golimumab is an approved drug (FDA (2009), EMA (2009))
Compound class:
Antibody
Comment: TNFα inhibitor.
Biosimilars:
View more information in the IUPHAR Pharmacology Education Project: golimumab |
| Immunopharmacology Disease | |||
| Disease | X-Refs | Comment | References |
| Psoriasis |
Disease Ontology:
DOID:8893 |
An anti-TNFα therapy approved for psoriasis. | |
| Rheumatoid arthritis |
Disease Ontology:
DOID:7148 OMIM: 180300 |
An anti-TNFα therapy approved for RA. | |
| Ulcerative colitis |
Disease Ontology:
DOID:8577 OMIM: 266600 Orphanet: ORPHA771 |
An anti-TNFα therapy approved for CD. | |
| Ankylosing spondylitis |
Disease Ontology:
DOID:7147 |
An anti-TNFα therapy approved for ankylosing spondylitis. | |
